TABLE 3.

Receptor-directed therapy for T-cell leukemia and lymphoma

Target	Description	Targeting Agent	References
CD2	LFA-3 (CD58) receptor	Alefacept (Amevive) Slipizumab (MEDI-507)	Majeau et al. (1994); Branco et al. (1999)
CD3	Signaling chain (CD3ζ) of the T-cell receptor (TCR)	Muromonab-CD3 (Orthoclone, OKT3)	Kung et al. (1979)
CD4	TCR co-receptor	Anti-Leu3a cM-T412 Zanolimumab (HuMax-CD4)	Knox et al. (1991); Knox et al. (1996); Kim et al. (2007)
CD5	Scavenger receptor family member	Anti-Leu1 T101 Anti-CD5-ricin A (CD5-Plus)	Muller et al. (1983); Dillman et al. (1984); Ravel et al. (1992)
CD25	IL-2 receptor α-subunit	Murine anti-Tac Daclizumab (Zenapax) Denileukin diftitox (Ontak)	Uchiyama et al. (1981a); Queen et al. (1989); Foss et al. (1998)
CD30	TNF receptor family member	Ber-H2 Hefi-1 MDX-060 SGN-30 SGN-35	Norton and Issacson (1987); Hecht et al. (1985); Borchmann et al., (2003); Bowen et al., (1993); Hamblett et al. (2005)
CD52	GPI-anchored glycoprotein	Alemtuzumab (Campath)	Hale et al. (1983)
CD122	IL-2 and IL-15 receptor β-subunit	Murine and humanized Mik-β1	Tsudo et al. (1989); Hakimi et al. (1993)